Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof

Patent metadata

Field	Value
Publication number	US-2016130307-A1
Application number	US-201514945384-A
Country	US
Kind code	A1
Filing date	Nov 18, 2015
Priority date	Jul 27, 2001
Publication date	May 12, 2016
Grant date	—

Abstract

The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.

First claim

1 . A method for inhibiting HBV infection of a cell in a subject, comprising administering to the subject a synthetic polypeptide of formula (I)
X-Y-Z   (I)
wherein X is an amino acid, or absent; Y is the amino acid sequence starting at amino acids at position 2 and ending at an amino acid between position 28 and position 48 of a pre-S1 region of HBV large (L) envelope protein; Z, linked to the —CO— group of the last residue of Y, is absent, or is the amino acid sequence starting at amino acid position 49 and ending at an amino acid between position 49 and position 78 of pre-S1 region of HBV L envelope protein, if the amino acid sequence of Y includes the amino acid at position 48; said polypeptide being chemically modified to bear a hydrophobic moiety.

2 . The method according to claim 1 , wherein the hydrophobic moiety is a saturated or unsaturated fatty acid having at least 4 carbon atoms.

3 . The method according to claim 1 , wherein the hydrophobic moiety is myristic acid or stearic acid.

4 . The method according to claim 1 , wherein the first amino acid of said polypeptide is chemically modified to bear the hydrophobic moiety.

5 . The method according to claim 1 , wherein said HBV L envelope protein is selected from the group consisting of HBV L envelope protein of human HBV, chimpanzee HBV strain LSH, woodchuck HBV, and Woolly Monkey HBV.

6 . The method according to claim 5 , wherein said human HBV is HBV strain alpha1.

7 . The method according to claim 5 , wherein said human HBV is HBV subtypes adr, ad, adw, adyw, ar or ayw.

8 . The method according to claim 1 , wherein the polypeptide has the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 13, and SEQ ID NO: 14.

9 . The method according to claim 1 , wherein the polypeptide consists of SEQ ID NO: 2.

10 . The method according to claim 9 , wherein the first amino acid of the polypeptide of SEQ ID NO: 2 is chemically modified to bear myristic acid or stearic acid.

Assignees

• Urban Stephan
• Inst Nat Sante Rech Med

Inventors

• Gripon Philippe
• Urban Stephan

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61P31/20

  for DNA viruses · CPC title

• C12N2730/10133

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title

• C07K14/005 Primary

  from viruses · CPC title